Arvinas

ARVN

Market cap $760M

11.84 USD

-1.25

9.55%

At close Updated Feb 12, 4:00 PM EST

Pre-market

After hours

11.80

-0.04

0.34%

1 day

-9.55%

5 days

-9.89%

1 month

-2.55%

3 months

13.74%

6 months

74.37%

Year to date

3.23%

1 year

-34.04%

5 years

-85.4%

10 years

-26.23%

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430

Healthcare Biotechnology